Nick Valiante, Founder & CEO, Glyde Bio, Inc.
An industry veteran (Chiron, Novartis, GSK, Moderna) with a track record of clinical advancement. 30 years of R&D experience in industrial immunology, vaccines, cancer, immunotherapy, drug discovery and clinical development. Has driven small molecule, recombinant proteins, nucleic acid and cell-based therapies to clinic and licensure. Key architect of mRNA 4157, Moderna’s/Merck’s best in class Personalized Cancer Vaccine. Currently leading Glyde’s mission to target glycan neoantigens on the cancer cell surface with therapeutic mAb, CAR cell and vaccines.